Laboratory for Physiology, Institute for Cardiovascular Research, VU Medical Center, Amsterdam, The Netherlands ; Johns Hopkins Bayview Proteomics Center, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America.
PLoS One. 2013 Oct 7;8(10):e74847. doi: 10.1371/journal.pone.0074847. eCollection 2013.
Protein kinase Cα (PKCα) is one of the predominant PKC isoforms that phosphorylate cardiac troponin. PKCα is implicated in heart failure and serves as a potential therapeutic target, however, the exact consequences for contractile function in human myocardium are unclear. This study aimed to investigate the effects of PKCα phosphorylation of cardiac troponin (cTn) on myofilament function in human failing cardiomyocytes and to resolve the potential targets involved.
Endogenous cTn from permeabilized cardiomyocytes from patients with end-stage idiopathic dilated cardiomyopathy was exchanged (∼69%) with PKCα-treated recombinant human cTn (cTn (DD+PKCα)). This complex has Ser23/24 on cTnI mutated into aspartic acids (D) to rule out in vitro cross-phosphorylation of the PKA sites by PKCα. Isometric force was measured at various [Ca(2+)] after exchange. The maximal force (Fmax) in the cTn (DD+PKCα) group (17.1±1.9 kN/m(2)) was significantly reduced compared to the cTn (DD) group (26.1±1.9 kN/m(2)). Exchange of endogenous cTn with cTn (DD+PKCα) increased Ca(2+)-sensitivity of force (pCa50 = 5.59±0.02) compared to cTn (DD) (pCa50 = 5.51±0.02). In contrast, subsequent PKCα treatment of the cells exchanged with cTn (DD+PKCα) reduced pCa50 to 5.45±0.02. Two PKCα-phosphorylated residues were identified with mass spectrometry: Ser198 on cTnI and Ser179 on cTnT, although phosphorylation of Ser198 is very low. Using mass spectrometry based-multiple reaction monitoring, the extent of phosphorylation of the cTnI sites was quantified before and after treatment with PKCα and showed the highest phosphorylation increase on Thr143.
PKCα-mediated phosphorylation of the cTn complex decreases Fmax and increases myofilament Ca(2+)-sensitivity, while subsequent treatment with PKCα in situ decreased myofilament Ca(2+)-sensitivity. The known PKC sites as well as two sites which have not been previously linked to PKCα are phosphorylated in human cTn complex treated with PKCα with a high degree of specificity for Thr143.
蛋白激酶 Cα(PKCα)是磷酸化肌钙蛋白的主要 PKC 同工酶之一。PKCα 与心力衰竭有关,是潜在的治疗靶点,然而,其对人类心肌收缩功能的确切影响尚不清楚。本研究旨在探讨 PKCα 对人心力衰竭肌钙蛋白(cTn)的磷酸化对肌球蛋白功能的影响,并确定涉及的潜在靶点。
用 PKCα 处理的重组人肌钙蛋白(cTn(DD+PKCα))交换终末期特发性扩张型心肌病患者心肌细胞通透化后的内源性 cTn(约 69%)。该复合物将肌钙蛋白 I 上的 Ser23/24 突变为天冬氨酸(D),以排除 PKCα 通过体外 PKA 位点交叉磷酸化。交换后,在不同的 [Ca(2+)]下测量等长力。cTn(DD+PKCα)组的最大力(Fmax)(17.1±1.9 kN/m(2))明显低于 cTn(DD)组(26.1±1.9 kN/m(2))。与 cTn(DD)相比,用 cTn(DD+PKCα)交换内源性 cTn 增加了力的 Ca(2+)敏感性(pCa50=5.59±0.02)。相反,随后用 PKCα 处理与 cTn(DD+PKCα)交换的细胞,使 pCa50 降低至 5.45±0.02。用质谱法鉴定了两个 PKCα 磷酸化残基:cTnI 上的 Ser198 和 cTnT 上的 Ser179,尽管 Ser198 的磷酸化程度很低。用基于质谱的多重反应监测法,在 PKCα 处理前后定量测定 cTnI 位点的磷酸化程度,结果显示 Thr143 的磷酸化增加最多。
PKCα 介导的 cTn 复合物磷酸化降低了 Fmax,增加了肌球蛋白的 Ca(2+)敏感性,而随后用 PKCα 在原位处理降低了肌球蛋白的 Ca(2+)敏感性。用 PKCα 处理的人心肌 cTn 复合物中,已知的 PKC 位点以及两个以前与 PKCα 无关的位点均发生了磷酸化,并且对 Thr143 具有高度特异性。